Spectral Medical (TSE:EDT) Hits New 12-Month Low – Should You Sell?

Shares of Spectral Medical Inc. (TSE:EDT) reached a new 52-week low during mid-day trading on Monday. The company traded as low as C$1.09 and last traded at C$1.18, with a volume of 13,200 shares changing hands. The stock had previously closed at C$1.07.

Spectral Medical Trading Up 10.3%

The firm has a market cap of C$346.39 million, a price-to-earnings ratio of -9.83 and a beta of 0.93. The company has a debt-to-equity ratio of 26.03, a quick ratio of 0.45 and a current ratio of 0.61. The business has a fifty day moving average of C$1.24 and a two-hundred day moving average of C$1.33.

Spectral Medical Company Profile

Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin¿ (‘PMX’). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s FDA cleared Endotoxin Activity Assay (EAA¿), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date.